Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Leukemogenic nucleophosmin mutation disrupts the transcription factor hub regulating granulo-monocytic fates

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Germline RBBP8 variants associated with early-onset breast cancer compromise replication fork stability

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Muscle-derived interleukin 6 increases exercise capacity by signaling in osteoblasts

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Breaking down brain barrier breaches in cerebral malaria

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Neutrophil extracellular traps - the dark side of neutrophils

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Papillon-Lefèvre syndrome patient reveals species-dependent requirements for neutrophil defenses

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Basement membrane stiffness determines metastases formation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Myelodysplastic syndrome patient-derived xenografts: from no options to many

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. ERG Controls B Cell Development by Promoting Igh V-to-DJ Recombination

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Xiaorong Gu
  • Quteba Ebrahem
  • Reda Z Mahfouz
  • Metis Hasipek
  • Francis Enane
  • Tomas Radivoyevitch
  • Nicolas Rapin
  • Bartlomiej Przychodzen
  • Zhenbo Hu
  • Ramesh Balusu
  • Claudiu V Cotta
  • David Wald
  • Christian Argueta
  • Yosef Landesman
  • Maria Paola Martelli
  • Brunangelo Falini
  • Hetty Carraway
  • Bo T Porse
  • Jaroslaw P Maciejewski
  • Babal K Jha
  • Yogen Saunthararajah
Vis graf over relationer

Nucleophosmin (NPM1) is amongst the most frequently mutated genes in acute myeloid leukemia (AML). It is not known, however, how the resulting oncoprotein mutant-NPM1 is leukemogenic. To reveal the cellular machinery in which NPM1 participates in myeloid cells, we analyzed the endogenous NPM1 protein-interactome by mass-spectrometry, and discovered abundant amounts of the master transcription factor driver of monocyte lineage-differentiation PU.1 (SPI1). Mutant-NPM1, which aberrantly accumulates in cytoplasm, dislocated PU.1 into cytoplasm with it. CEBPA and RUNX1, the master transcription factors that collaborate with PU.1 to activate granulo-monocytic lineage-fates, remained nuclear, but without PU.1, their coregulator interactions were toggled from coactivators to corepressors, repressing instead of activating greater than 500 granulocyte and monocyte terminal-differentiation genes. An inhibitor of nuclear export, selinexor, by locking mutant-NPM1/PU.1 in the nucleus, activated terminal monocytic fates. Direct depletion of the corepressor DNA methyltransferase 1 (DNMT1) from the CEBPA/RUNX1 protein interactome using the clinical drug decitabine activated terminal granulocytic fates. Together, these non-cytotoxic treatments extended survival by greater than 160 days versus vehicle in a patient-derived xenotransplant model of NPM1/FLT3-mutated AML. In sum, mutant-NPM1 represses monocyte and granulocyte terminal-differentiation by disrupting PU.1/CEBPA/RUNX1 collaboration, a transforming action that can be reversed by pharmacodynamically-directed dosing of clinical small molecules.

OriginalsprogEngelsk
TidsskriftThe Journal of clinical investigation
Vol/bind128
Udgave nummer10
Sider (fra-til)4260-4279
ISSN0021-9738
DOI
StatusUdgivet - 1 okt. 2018

ID: 54954225